DE10105038B4 - Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems - Google Patents
Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems Download PDFInfo
- Publication number
- DE10105038B4 DE10105038B4 DE10105038A DE10105038A DE10105038B4 DE 10105038 B4 DE10105038 B4 DE 10105038B4 DE 10105038 A DE10105038 A DE 10105038A DE 10105038 A DE10105038 A DE 10105038A DE 10105038 B4 DE10105038 B4 DE 10105038B4
- Authority
- DE
- Germany
- Prior art keywords
- sub
- alkyl
- alkoxy
- pro
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 7
- 210000000653 nervous system Anatomy 0.000 title claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 24
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 20
- 150000001413 amino acids Chemical class 0.000 claims abstract description 20
- 125000005843 halogen group Chemical group 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 18
- 230000000472 traumatic effect Effects 0.000 abstract description 5
- 230000000302 ischemic effect Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- -1 Val Chemical compound 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 102000007072 Nerve Growth Factors Human genes 0.000 description 8
- 230000008499 blood brain barrier function Effects 0.000 description 8
- 210000001218 blood-brain barrier Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 102000015336 Nerve Growth Factor Human genes 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000001787 dendrite Anatomy 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 238000004617 QSAR study Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 239000003900 neurotrophic factor Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- CAOGSKOCNQRIOG-GJZGRUSLSA-N tert-butyl n-[(2s)-1-[(2s)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CC=CC=C1 CAOGSKOCNQRIOG-GJZGRUSLSA-N 0.000 description 4
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000003018 neuroregenerative effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 102100029268 Neurotrophin-3 Human genes 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 229940097998 neurotrophin 4 Drugs 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- 102000038778 CNTF family Human genes 0.000 description 1
- 108091064557 CNTF family Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710154250 Small basic protein Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000002555 anti-neurodegenerative effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- BLWYXBNNBYXPPL-YFKPBYRVSA-N methyl (2s)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1 BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 238000003522 neurite outgrowth assay Methods 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002862 plasmatocyte Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10105038A DE10105038B4 (de) | 2001-02-05 | 2001-02-05 | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
| AT02719767T ATE285244T1 (de) | 2001-02-05 | 2002-02-05 | Tripeptide und deren derivate zur behandlung von postläsionalen krankheiten des nervensystems |
| DE60202356T DE60202356T2 (de) | 2001-02-05 | 2002-02-05 | Tripeptide und deren derivate zur behandlung von postläsionalen krankheiten des nervensystems |
| PT02719767T PT1363656E (pt) | 2001-02-05 | 2002-02-05 | Tripeptideos e derivados de tripeptideos para o tratamento de doencas pos-lesionais do sistema nervoso |
| ES02719767T ES2230480T3 (es) | 2001-02-05 | 2002-02-05 | Tripeptidos y derivados de tripeptidos para el tratamiento de enfermedades potlesionales del sistema nervioso. |
| JP2002562379A JP4183507B2 (ja) | 2001-02-05 | 2002-02-05 | 神経系の損傷後疾患の処置のためのトリペプチド及びトリペプチド誘導体 |
| EP02719767A EP1363656B1 (en) | 2001-02-05 | 2002-02-05 | Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| PCT/EP2002/001183 WO2002062373A2 (en) | 2001-02-05 | 2002-02-05 | Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| US10/635,805 US7122524B2 (en) | 2001-02-05 | 2003-08-05 | Tripeptides and tripeptide derivatives for the treatment of postlesional disease of the nervous system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10105038A DE10105038B4 (de) | 2001-02-05 | 2001-02-05 | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE10105038A1 DE10105038A1 (de) | 2002-08-14 |
| DE10105038B4 true DE10105038B4 (de) | 2005-07-07 |
Family
ID=7672831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10105038A Expired - Fee Related DE10105038B4 (de) | 2001-02-05 | 2001-02-05 | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
| DE60202356T Expired - Lifetime DE60202356T2 (de) | 2001-02-05 | 2002-02-05 | Tripeptide und deren derivate zur behandlung von postläsionalen krankheiten des nervensystems |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60202356T Expired - Lifetime DE60202356T2 (de) | 2001-02-05 | 2002-02-05 | Tripeptide und deren derivate zur behandlung von postläsionalen krankheiten des nervensystems |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7122524B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1363656B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4183507B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE285244T1 (cg-RX-API-DMAC7.html) |
| DE (2) | DE10105038B4 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2230480T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1363656E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002062373A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10105038B4 (de) | 2001-02-05 | 2005-07-07 | Neurotell Ag | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
| DE10105041A1 (de) | 2001-02-05 | 2002-08-14 | Tell Pharm Ag Hergiswil | Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten |
| DE10105040A1 (de) | 2001-02-05 | 2002-08-14 | Tell Pharm Ag Hergiswil | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
| JP2011201923A (ja) * | 2005-07-01 | 2011-10-13 | Snow Brand Milk Products Co Ltd | ジペプチジルペプチダーゼｉｖ阻害剤 |
| CN106317177A (zh) * | 2015-06-23 | 2017-01-11 | 首都医科大学 | Gly-Phe-Pro,其合成,活性和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1323301C (en) * | 1987-06-05 | 1993-10-19 | Alan I. Faden | Thyrotropin-releasing hormone analogs in cns injury |
| FR2622581B1 (fr) * | 1987-11-03 | 1990-02-16 | Inorgan Sa Rech Develop Pharm | Nouveaux derives de l-proline, leur preparation et leurs applications biologiques |
| EP0445606B1 (en) * | 1990-02-27 | 1997-01-22 | The Agency of Industrial Science and Technology | Novel oligopeptides, pharmaceutical composition and food containing the same, and use of oligopeptides |
| DE4007869A1 (de) | 1990-03-13 | 1991-09-19 | Merck Patent Gmbh | Aminosaeurederivate |
| JPH045240A (ja) | 1990-04-20 | 1992-01-09 | Taisho Pharmaceut Co Ltd | 抗痴呆剤 |
| US5091391A (en) * | 1990-08-16 | 1992-02-25 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
| JPH06504061A (ja) | 1990-12-28 | 1994-05-12 | コーテックス ファーマシューティカルズ インコーポレイテッド | 神経変性の治療および予防におけるカルパイン阻害剤の使用 |
| WO1992013549A1 (en) * | 1991-02-07 | 1992-08-20 | Research Corporation Technologies, Inc. | Inhibition of cell proliferation by hydrophobic peptides |
| US6235929B1 (en) | 1991-12-27 | 2001-05-22 | Georgia Tech Research Corporation | Tripeptide α-ketoamides |
| ZA95260B (en) * | 1994-01-13 | 1995-09-28 | Univ Columbia | Synthetic receptors libraries and uses thereof |
| US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5834029A (en) | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
| JPH0940577A (ja) * | 1995-05-24 | 1997-02-10 | Mitsui Toatsu Chem Inc | トリペプチド、ジペプチドを含有する医薬組成物 |
| EP0840614A1 (en) | 1995-06-13 | 1998-05-13 | Sanofi Winthrop, Inc. | Calpain inhibitors for the treatment of neurodegenerative diseases |
| JPH09169797A (ja) * | 1995-12-22 | 1997-06-30 | Mitsui Toatsu Chem Inc | プロテアーゼアクティベーター活性を有するペプチド |
| US5840838A (en) * | 1996-02-29 | 1998-11-24 | University Of Kentucky Research Foundation | Process for enhancing the activity of amyloid β peptides |
| JP2001501930A (ja) * | 1996-10-04 | 2001-02-13 | オークランド ユニサーヴィスィズ リミテッド | 神経酵素の調節 |
| JP4727770B2 (ja) | 1997-09-26 | 2011-07-20 | カルピス株式会社 | 尿中カテコールアミン低下、尿中ノルアドレナリン低下、尿中ドーパミン低下及びＦｉｓｃｈｅｒ比低下の少なくとも１つの軽減剤 |
| US6080848A (en) * | 1998-05-01 | 2000-06-27 | Incyte Pharmaceuticals, Inc. | Human brain associated protein |
| US6379691B1 (en) * | 1998-09-29 | 2002-04-30 | Medtronic/Ave, Inc. | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
| AU1574701A (en) * | 1999-10-22 | 2001-04-30 | Wrair Walter Reed Army Institute Of Research | A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same |
| JP4633876B2 (ja) | 1999-11-11 | 2011-02-16 | カルピス株式会社 | トリペプチドの製造方法 |
| WO2001068114A1 (en) | 2000-03-10 | 2001-09-20 | Monsanto Company | Novel peptides with anti-hypertensive activity |
| DE10105041A1 (de) | 2001-02-05 | 2002-08-14 | Tell Pharm Ag Hergiswil | Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten |
| DE10105038B4 (de) | 2001-02-05 | 2005-07-07 | Neurotell Ag | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
| US6846641B2 (en) * | 2002-04-23 | 2005-01-25 | Agy Therapeutics, Inc. | In vitro ischemia model |
-
2001
- 2001-02-05 DE DE10105038A patent/DE10105038B4/de not_active Expired - Fee Related
-
2002
- 2002-02-05 PT PT02719767T patent/PT1363656E/pt unknown
- 2002-02-05 EP EP02719767A patent/EP1363656B1/en not_active Expired - Lifetime
- 2002-02-05 JP JP2002562379A patent/JP4183507B2/ja not_active Expired - Fee Related
- 2002-02-05 WO PCT/EP2002/001183 patent/WO2002062373A2/en not_active Ceased
- 2002-02-05 ES ES02719767T patent/ES2230480T3/es not_active Expired - Lifetime
- 2002-02-05 AT AT02719767T patent/ATE285244T1/de not_active IP Right Cessation
- 2002-02-05 DE DE60202356T patent/DE60202356T2/de not_active Expired - Lifetime
-
2003
- 2003-08-05 US US10/635,805 patent/US7122524B2/en not_active Expired - Fee Related
Non-Patent Citations (6)
| Title |
|---|
| CAPLUS-Abstr. 103:172 227 zu Faden, A. [u.a.]: Effect of TRH analogs on neurologic recovery after experimental spinal trauma. In: Neurology, 1985, Vol. 35, No. 9, S. 1331-4 |
| CAPLUS-Abstr. 103:172 227 zu Faden, A. [u.a.]: Effect of TRH analogs on neurologic recovery afterexperimental spinal trauma. In: Neurology, 1985, Vol. 35, No. 9, S. 1331-4 * |
| EMBASE-Abstr. 881 60 985 zu Guiloff R.J.: Thyro- tropin releasing hormone and motorneurone disease. In: Reviews in the Neurosciences, 1987, Vol. 1, No. 3-4, S. 201-219 |
| EMBASE-Abstr. 881 60 985 zu Guiloff R.J.: Thyro- tropin releasing hormone and motorneurone disease.In: Reviews in the Neurosciences, 1987, Vol. 1, No. 3-4, S. 201-219 * |
| Szirtes, T. [u.a.]: Synthesis of Thyrotropin-Rel- easing Hormone Analogues. 1. Complete Dissociation of Central Nervous System Effects from Thyrotro- pin-Releasing Activity. In: J. Med. Chem. 1984, Vol. 27, S. 741-745 |
| Szirtes, T. [u.a.]: Synthesis of Thyrotropin-Rel- easing Hormone Analogues. 1. Complete Dissociationof Central Nervous System Effects from Thyrotro- pin-Releasing Activity. In: J. Med. Chem. 1984, Vol. 27, S. 741-745 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004526702A (ja) | 2004-09-02 |
| ES2230480T3 (es) | 2005-05-01 |
| DE10105038A1 (de) | 2002-08-14 |
| US7122524B2 (en) | 2006-10-17 |
| US20050080016A1 (en) | 2005-04-14 |
| DE60202356T2 (de) | 2005-12-08 |
| DE60202356D1 (de) | 2005-01-27 |
| WO2002062373A3 (en) | 2002-11-14 |
| PT1363656E (pt) | 2005-03-31 |
| JP4183507B2 (ja) | 2008-11-19 |
| EP1363656B1 (en) | 2004-12-22 |
| ATE285244T1 (de) | 2005-01-15 |
| WO2002062373A2 (en) | 2002-08-15 |
| EP1363656A2 (en) | 2003-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69100128T2 (de) | TRH-Derivate, deren Herstellung und pharmazeutische Zusammensetzungen. | |
| DE3785684T2 (de) | Pyrrolidinamid-Derivate von Acylaminosäure, pharmazeutische Zusammensetzung und Verwendung. | |
| DE69532475T2 (de) | Krebs hemmende peptide | |
| DE69024965T2 (de) | Dehydrodidemnin b | |
| EP0090341B1 (de) | Spiro(4.(3+n))-2-aza-alkan-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung | |
| DE2602193A1 (de) | Peptid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| DE2755036A1 (de) | Pseudopeptide, verfahren zu deren herstellung und dieselben enthaltendes pharmazeutisches mittel | |
| DE3024256C2 (cg-RX-API-DMAC7.html) | ||
| DE3884139T2 (de) | L-Prolin-Derivate, deren Herstellung und deren biologische Anwendungen. | |
| DE69006116T2 (de) | Peptid-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen. | |
| EP0490379A2 (de) | Diaminosäurederivate und pharmazeutische Zusammensetzungen | |
| DE3177306T2 (de) | Verfahren und Verbindungen zur Herstellung von H-ARG-X-Z-Y-TYR-R. | |
| DE10105038B4 (de) | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems | |
| DE10105041A1 (de) | Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten | |
| EP0110224A2 (de) | Benzoylthioverbindungen, ihre Herstellung und Verwendung als Arzneimittel | |
| CH649562A5 (de) | Derivate des methionin-enzephalins. | |
| CH655929A5 (de) | Biologisch wirksame 2,5-piperazindionderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zubereitungen. | |
| DE3200662C2 (de) | Nitrosoharnstoffderivate, Verfahren zu deren Herstellung und Arzneimittel diese enthaltend | |
| DE2112057A1 (de) | Neue Penicillinester | |
| DE69425734T2 (de) | Aureobasidine | |
| DE2343035A1 (de) | Tripeptide mit antidepressiver und prolactinausschuettender wirkung und verfahren zu ihrer herstellung | |
| DE2817923C2 (de) | Septacidinverbindungen und diese enthaltende Arzneimittel | |
| DE69615845T2 (de) | Polycyclische alkaloid-derivate als nmda-rezeptor-antagonisten | |
| EP0307553B1 (de) | Modifizierte Splenopentine, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| EP0033504B1 (de) | Pentapeptide vom Encephalintyp, Verfahren zur Herstellung derselben und diese enthaltende Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |